Tessera Defense and Homeland Security (HLSQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Oct, 2026Executive summary
October 7, 2026 employment agreements set compensation for CEO Michael Oster and CFO David Rokach; equity awards are conditional on stockholder approval of an expanded 2026 Equity Incentive Plan.
A Special Meeting is scheduled for October 20, 2026 to consider increasing plan shares from 685,000 to 6,000,000; NYSE American approval to list underlying shares is also required.
Voting matters and shareholder proposals
Stockholders are asked to approve the plan amendment increasing shares reserved for issuance from 685,000 to 6,000,000 at the October 20, 2026 Special Meeting.
The proposed amendment is a condition to Oster's and Rokach's specified equity awards; the awards also require applicable corporate approvals, and listing approval for the underlying shares.
Board of directors and corporate governance
The Compensation Committee and Board approved Oster's and Rokach's agreements on October 7, 2026; each executive is excluded from discussion and voting on approval of his own agreement.
Oster reports to the boards of the parent and Israeli subsidiary; his duties include strategy, risk management, financial reporting, compliance and investor relations.
Rokach serves as CFO, reports to Oster at the subsidiary, and shares board oversight; Oster is also acting Chairman of subsidiary boards.
Latest events from Tessera Defense and Homeland Security
- CEO and CFO awards hinge on Proposal 1 approval, with additional shares tied to future performance.HLSQ
Proxy filing - Vote centers on a 5.315 million-share plan increase and potential dilution.HLSQ
Proxy filing - Vote sought to expand equity plan by 5.3M shares to support growth and retention.HLSQ
Proxy filing - First defense-tech revenue reported post-acquisitions, but liquidity and going concern risks persist.HLSQ
Q2 2026 - Proxy seeks approval for DFSL acquisition securities, reverse split, and auditor ratification.HLSQ
Proxy filing - Stockholders to vote on acquisition-related securities issuance, reverse split, and auditor change.HLSQ
Proxy filing - Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.HLSQ
Registration filing - Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.HLSQ
Q2 2024 - BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.HLSQ
Q4 2024 & Study Result